Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
Jeffrey Cohen, MD: I think the last couple years have been difficult for scientific meetings. So, I think probably the one thing I'm the most looking forward to is getting together face-to-face with my peers. We were able to have two meetings virtually over the last couple years, but now we'd like to get together in person.
One of the things we've always tried to do with the ACTRIMS forum is to have a single track oriented around a specific theme. The theme for this year's meeting is, is biomarkers, so these are the tests that we use to assess various aspects of multiple sclerosis. There will be sessions on biomarkers to detect the disease before it presents clinically, to understand the disease process, and to monitor the disease, and response to therapy. That's the main theme of the meeting, and then there are a number of other components to the meeting added on to that.
Transcript edited for clarity.